NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Moderna, Inc. MRNA
10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.9B
▼ 39.9% vs FY2024
EPS · FY25
$-7.26
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-28.9%
Net margin · FY25
-145.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.9B
Revenue, FY2025 · full 10-year series below
Revenue
Net income
The company lost 145 cents on every revenue dollar this year.
Per share
USD -7.26
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-28.9%
Return on equity, FY2025
ROE
Operating margin-158.1%
Net margin-145.2%
Return on assets-21.3%
Each USD of equity lost 29 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD -15.0M
Share of profit-0.0%
Consecutive raises—
Growth
+19.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−53.4%
+19.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.39B
Shares outstanding, FY2025
Change, 5 years−1.3%
Change, 10 years—
The share count shrank 1% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 12.3B
total assets, end of FY2025
Total assetsUSD 12.3B
EquityUSD 8.7B
CashUSD 2.6B
Gross debtUSD 590.0M
Net debtUSD -2.0B
Current ratio3.29×
The company holds more cash than debt.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
1.9
3.2
6.8
19.3
18.5
0.8
0.1
0.1
0.2
0.1
Operating income $B
−3.1
−3.9
−4.2
9.4
13.3
−0.8
−0.5
−0.4
−0.3
−0.2
EBITDA $B
−2.9
−3.8
−3.6
9.8
13.5
−0.7
−0.5
−0.4
−0.2
−0.2
Income tax $B
0.1
−0.0
0.8
1.2
1.1
0.0
−0.0
0.0
−0.0
0.0
Net income $B
−2.8
−3.6
−4.7
8.4
12.2
−0.7
−0.5
−0.4
−0.3
−0.2
EPS, diluted $
−7.26
−9.28
−12.33
20.12
28.29
−1.96
−1.55
−4.95
−4.18
−3.79
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
−28.9
−28.8
−28.6
50.3
146.1
−40.0
−38.0
−78.6
·
·
Shares out B
0.39
0.39
0.38
0.39
0.40
0.40
0.34
0.33
0.07
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
28 of 28
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed